Business
Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
Topline data from MISSION Phase 2 trial of zetomipzomib for the treatment of lupus nephritis expected in June 2022, consistent with previous guidance KZR-261
About this update from Kezar Life Sciences, Inc.
[{"type":"text","content":"\n\nTopline data from MISSION Phase 2 trial of zetomipzomib for the treatment of lupus nephritis expected in June 2022, consistent with previous guidance\n\n\nKZR-261 continues to enroll patients with solid tumors in Phase 1 dose-escalation trial\n\n\nCompany to host virtual Investor and Analyst Day in June 2022\n\n\nCash, cash equivalents and marketable securities totaled $242.6 million as of March 31, 2022\n\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nKezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.\n\n“I want to thank my colleagues at Kezar for their excellent execution across both of our novel programs so far this year,” said John Fowler, Kezar’s Co-founder and CEO. “We are excited to present the topline results from our Phase 2 MISSION trial in lupus nephritis this June and remain committed to exploring zetomipzomib’s potential in inflammatory diseases with high unmet need. Our strengthened balance sheet is key in supporting both of our programs, including our Phase 1 trial of KZR-261 in solid tumors.”\n\nZetomipzomib: Selective Immunoproteasome Inhibitor\n\nMISSION – Phase 2 clinical trial of zetomipzomib (KZR-616) in patients with lupus nephritis (LN) (NCT03393013)\n\n\nIn November 2021, Kezar reported interim data from the MISSION Phase 2 open-label trial in patients with active, proliferative LN. The interim data showed that, of the five patients who completed the full 24 weeks of weekly treatment with zetomipzomib 60mg doses, two achieved partial renal responses (PRRs) and two achieved complete renal responses (CRRs). The primary efficacy endpoint for the trial is the number of patients achieving a renal response measured by a 50% or greater reduction in UPCR at the end of treatment compared to baseline.\n\n\nKezar reiterates prior guidance and expects to report Phase 2 topline data in June 2022\n\n\n\n\nAn abstract featuring zetomipzomib has been selected for poster presentation as part of the EULAR Science Exhibit session at the upcoming Annual European Congress of Rheumatology (EULAR), taking place June 1-4, 2022, in Copenhagen, Denmark. The virtual presentation will be availab...